Activating mutations in the tyrosine kinase domain of HER2 Naftopidil (Flivas)

Activating mutations in the tyrosine kinase domain of HER2 Naftopidil (Flivas) (ErbB2) have been identified in human cancers. HER2 in mammary epithelial cells activated autocrine transforming growth factor (TGF) β1 signaling through a mechanism involving Rac1 and JNK-AP1-dependent transcription. Cells transformed by an activating mutant of H-Ras (G12V) also expressed higher TGF-β1 level through Rac1… Continue reading Activating mutations in the tyrosine kinase domain of HER2 Naftopidil (Flivas)